These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36858065)

  • 1. [Treatment and LDL cholesterol adjustment in patients with high and very high cardiovascular risk in Germany compared with Europe - data from the SANTORINI registry].
    Stürzebecher PE; Tünnemann-Tarr A; Tuppatsch K; Laufs U
    Dtsch Med Wochenschr; 2023 Apr; 148(9):55-64. PubMed ID: 36858065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.
    Ray KK; Haq I; Bilitou A; Manu MC; Burden A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL;
    Lancet Reg Health Eur; 2023 Jun; 29():100624. PubMed ID: 37090089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study.
    Ray KK; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Laufs U; Mostaza JM; Nanchen D; Bardet A; Lamparter M; Chhabra R; Soronen J; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL;
    Eur J Prev Cardiol; 2024 Nov; 31(15):1792-1803. PubMed ID: 38861400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study.
    Ray KK; Haq I; Bilitou A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Hildebrandt P; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
    Atheroscler Plus; 2021 Sep; 43():24-30. PubMed ID: 36644508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
    Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
    Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
    Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
    van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
    Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
    Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
    Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
    Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
    Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands.
    Heintjes EM; Anastassopoulou A; Kuiper J; Bilitou A; Beest FJAP; Herings RMC; Postma MJ; Jukema JW
    Curr Med Res Opin; 2023 Jan; 39(1):1-11. PubMed ID: 36168818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines.
    Raygor V; Khera A
    Curr Cardiol Rep; 2020 Jul; 22(9):87. PubMed ID: 32647997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
    Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF
    Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
    De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
    Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?
    Averna M; Catapano AL
    Eur J Intern Med; 2022 Jan; 95():1-4. PubMed ID: 34728127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
    Reynolds TM; Pottle A; Quoraishi SH
    Vasc Health Risk Manag; 2021; 17():227-237. PubMed ID: 34054297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.